Viridian Therapeutics, Inc.\DE (VRDN) Other financing activities (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Other financing activities history runs 12 years deep, the most recent figure standing at $287.9 million for Q4 2025.

• In Q4 2025, Other financing activities rose 176.09% year-over-year to $287.9 million; the TTM figure through Mar 2026 stood at $287.4 million (up 4028.61% YoY), while the FY2025 annual figure was $289.1 million, up 5308.91% from the prior year.
• Other financing activities for Q4 2025 stood at $287.9 million, up from -$498000.0 in the prior quarter.
• The five-year high for Other financing activities was $383.4 million in Q3 2024, with the low at -$378.4 million in Q4 2024.
• The 5-year median for Other financing activities is $908000.0 (2022), against an average of $19.7 million.
• The sharpest annual moves came in 2023 and 2024: Other financing activities tumbled 1035.13% in 2023, then surged 4615.29% in 2024.
• Viridian Therapeutics, Inc.\DE's Other financing activities stood at -$900000.0 in 2021, then rose by 19.44% to -$725000.0 in 2022, then sank by 1071.17% to -$8.5 million in 2023, then sank by 4356.54% to -$378.4 million in 2024, then jumped by 176.09% to $287.9 million in 2025.
• Business Quant data shows VRDN's Other financing activities at $287.9 million in Q4 2025, -$498000.0 in Q3 2025, and $1.6 million in Q1 2025.